Literature DB >> 11413316

Mutations that increase in situ priming also decrease circularization for duck hepatitis B virus.

D D Loeb1, R Tian.   

Abstract

The process of hepadnavirus reverse transcription involves two template switches during the synthesis of plus-strand DNA. The first involves translocation of the plus-strand primer from its site of generation, the 3' end of minus-strand DNA, to the complementary sequence DR2, located near the 5' end of the minus-strand DNA. Plus strands initiated from DR2 are extended to the 5' end of the minus-strand DNA. At this point, the 3' end of the minus strand becomes the template via the second template switch, a process called circularization. Elongation of circularized plus-strand DNA generates relaxed circular DNA. Although most virions contain relaxed circular DNA, some contain duplex linear DNA. Duplex linear genomes are synthesized when the plus-strand primer is used at the site of its generation, the 3' end of the minus-strand template. This type of synthesis is called in situ priming. Although in situ priming is normally low, in some duck hepatitis B virus mutants this type of priming is elevated. For example, mutations within the 3' end of the minus-strand DNA can lead to increased levels of in situ priming. We report here that these same mutations result in a second defect, a less efficient template switch that circularizes the genome. Although it is not clear how these mutations affect both steps in DNA replication, our findings suggest a commonality in the mechanism of initiation of plus-strand synthesis and the template switch that circularizes the genome.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11413316      PMCID: PMC114372          DOI: 10.1128/JVI.75.14.6492-6497.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  21 in total

1.  Low dynamic state of viral competition in a chronic avian hepadnavirus infection.

Authors:  Y Y Zhang; J Summers
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

2.  Sequence identity of the terminal redundancies on the minus-strand DNA template is necessary but not sufficient for the template switch during hepadnavirus plus-strand DNA synthesis.

Authors:  D D Loeb; K J Gulya; R Tian
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

3.  Mutations within DR2 independently reduce the amount of both minus- and plus-strand DNA synthesized during duck hepatitis B virus replication.

Authors:  D D Loeb; R Tian; K J Gulya
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

4.  cis-Acting sequences in addition to donor and acceptor sites are required for template switching during synthesis of plus-strand DNA for duck hepatitis B virus.

Authors:  M B Havert; D D Loeb
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

5.  Illegitimate replication of linear hepadnavirus DNA through nonhomologous recombination.

Authors:  W Yang; J Summers
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

6.  Replication of the genome of a hepatitis B--like virus by reverse transcription of an RNA intermediate.

Authors:  J Summers; W S Mason
Journal:  Cell       Date:  1982-06       Impact factor: 41.582

7.  Previously unsuspected cis-acting sequences for DNA replication revealed by characterization of a chimeric heron/duck hepatitis B virus.

Authors:  K Mueller-Hill; D D Loeb
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

8.  Transfer of the minus strand of DNA during hepadnavirus replication is not invariable but prefers a specific location.

Authors:  D D Loeb; R Tian
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

9.  Comparative sequence analysis of duck and human hepatitis B virus genomes.

Authors:  R Sprengel; C Kuhn; H Will; H Schaller
Journal:  J Med Virol       Date:  1985-04       Impact factor: 2.327

10.  Infection of ducklings with virus particles containing linear double-stranded duck hepatitis B virus DNA: illegitimate replication and reversion.

Authors:  W Yang; J Summers
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

View more
  7 in total

1.  cis-Acting sequences that contribute to the synthesis of relaxed-circular DNA of human hepatitis B virus.

Authors:  Ning Liu; Lin Ji; Megan L Maguire; Daniel D Loeb
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

2.  Analysis of duck hepatitis B virus reverse transcription indicates a common mechanism for the two template switches during plus-strand DNA synthesis.

Authors:  Michael B Havert; Lin Ji; Daniel D Loeb
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

3.  cis-Acting sequences 5E, M, and 3E interact to contribute to primer translocation and circularization during reverse transcription of avian hepadnavirus DNA.

Authors:  Karlyn Mueller-Hill; Daniel D Loeb
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

4.  Characterization of the intracellular deproteinized relaxed circular DNA of hepatitis B virus: an intermediate of covalently closed circular DNA formation.

Authors:  Haitao Guo; Dong Jiang; Tianlun Zhou; Andrea Cuconati; Timothy M Block; Ju-Tao Guo
Journal:  J Virol       Date:  2007-09-05       Impact factor: 5.103

5.  The conformation of the 3' end of the minus-strand DNA makes multiple contributions to template switches during plus-strand DNA synthesis of duck hepatitis B virus.

Authors:  Jeffrey W Habig; Daniel D Loeb
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

6.  DNA Polymerase alpha is essential for intracellular amplification of hepatitis B virus covalently closed circular DNA.

Authors:  Liudi Tang; Muhammad Sheraz; Michael McGrane; Jinhong Chang; Ju-Tao Guo
Journal:  PLoS Pathog       Date:  2019-04-26       Impact factor: 6.823

7.  Virological pattern of hepatitis B infection in an HIV-positive man with fatal fulminant hepatitis B: a case report.

Authors:  Sabrina Bagaglio; Luca Albarello; Priscilla Biswas; Caterina Uberti-Foppa; Claudio Fortis; Giulia Morsica
Journal:  J Med Case Rep       Date:  2009-11-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.